HK inno.N signs deal to produce Brexogen's exosome therapy

HK inno.N said on Thursday that it signed a business agreement with Brexogen, a company specializing in exosome therapeutics, to produce cell lines for the development of exosome therapeutics derived from stem cells.

Accordingly, the production will be carried out at HK inno.N's Cell and Gene (C&G) Center in Hanam, Gyeonggi Province.

Exosomes are nanoparticles secreted by cells, and domestic and foreign pharmaceutical companies are utilizing exosomes to develop biomarkers, drug delivery systems, and therapeutics.

In the case of existing stem cell-derived exosome therapeutics, one of the limitations has been the difficulty of obtaining high-purity exosomes and mass production due to the different states of exosomes produced within cells.

In partnership with HK inno.N, Brexogen is developing various exosome therapeutics that overcome these limitations. Brexogen's exosome platform, BG-Platform, maximizes the efficacy of stem cells that produce exosomes while controlling the active ingredients in exosomes. The platform has the scalability to develop exosome therapeutics targeting various diseases with different mechanisms of action.

In 2020, HK inno.N established the C&G Center in Hanam, Gyeonggi Province, as an innovative platform and received a license to manufacture advanced biopharmaceuticals last year. Aside from the CAR-T and CAR-NK cell gene therapy research conducted at the center, the company also is also carrying out joint research projects with domestic companies such as GC Cells, GI Cell, Cell In Cells, and AinB, as well as contract manufacturing and outsourced development.

"Based on our GMP-based technology and know-how, we will make every effort to successfully develop exosome therapeutics using Brexogen's core technology," said HK inno.N Executive Director of the researcher center, Won Sung-yong.

Brexogen CEO Kim Soo also added that the company will strive to diversify the development of exosome therapeutics and quickly lead the global exosome market through the collaboration with HK inno.N.